The same hormone can appear in an approved manufactured medicine and a compounded preparation. That shared ingredient does not make the finished products equivalent or give them the same regulatory status.
For a menopause treatment, ask which category the actual prescription belongs to. This is more useful than labeling an entire clinic approved or compounded, because some providers offer products in both categories.
In this entry
Approval belongs to a specific medicine
The FDA evaluates evidence and manufacturing information for an approved product’s proposed uses. Compounded drugs do not go through that same premarket approval process. Their preparation may address an individual need, but their finished formulation is not FDA-approved.
The distinction also explains why FDA registration of a facility is not enough to establish product approval. Ask the prescriber a direct question about the medicine itself. If the answer describes only the ingredient or pharmacy, the original question remains unanswered.
Bioidentical is a different descriptor
Bioidentical means a hormone has the same molecular structure as the corresponding hormone in the body. FDA-approved estradiol and micronized progesterone products can meet that description. It is therefore inaccurate to imply that a patient must use compounding to obtain bioidentical hormones.
Plant-derived language does not settle safety, either. Ingredients can be processed into medicines with real effects and real risks. The medical history, formulation and treatment goal still matter.
Ask what problem compounding solves
A particular patient may need a formulation or ingredient change that a suitable approved medicine cannot provide. The clinician should explain that need and the alternatives considered. A promise of individualized balance or a convenient combined cream does not supply the same clinical rationale.
ACOG advises against routine compounded menopausal hormone therapy when appropriate approved options are available. Its guidance also cautions against using routine saliva or urine hormone tests to guide these prescriptions. Ask what evidence supports the actual preparation rather than a general ingredient.
Look closely at combined formulas
Several hormones in one cream can sound simpler than separate medicines. But delivery through the skin may not provide the same exposure as an oral or approved transdermal product. The concern is especially important when progesterone is intended to protect the uterine lining during systemic estrogen use.
Ask how that protection is established and what the plan is for unexpected bleeding. Our progesterone guide explains why this is a safety question rather than a packaging preference.
Use provider reviews as a map
Winona and Defy describe compounded options. Alloy identifies an approved estradiol patch. Evernow describes a menu that spans categories. None of those labels chooses the right prescription for you.
The compounded-care shortlist includes approved alternatives to keep the choice in context. Its first position is promotional, and CoreAge Rx’s HRT availability remains unconfirmed. A provider’s position in a list does not establish a reason to use an unapproved preparation.
Use the distinction in a provider comparison
Read Inner Balance for a compounded combination, Hone for a menu with differing preparation categories and MyMenopauseRx for approved estradiol and progesterone options. The question is the status of the finished prescription, not a broad label applied to a clinic.
Apply the distinction to another provider
Fem Excel explicitly describes compounded hormones. Alpha Hormones discusses customized Bi-Est, while the current Amazing Meds pages do not establish a complete formulation catalog. A provider-wide label cannot replace checking the actual prescription.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.